ISOFOL MEDICAL AB |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.688 SEK | -2.96% |
|
-3.78% | -5.75% |
| Feb. 20 | Isofol Medical AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
| Feb. 20 | Isofol Medical AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 12.8 136.25 | Sales 2023 | 0.72 7.68 | Capitalization | 118M 1.26B |
|---|---|---|---|---|---|
| Net income 2022 | -160M -1.7B | Net income 2023 | -37M -394M | EV / Sales 2022 | -5,244,477 x |
| Net cash position 2022 | 187M 1.99B | Net cash position 2023 | 138M 1.47B | EV / Sales 2023 | -28,074,520 x |
| P/E ratio 2022 |
-0.75
x | P/E ratio 2023 |
-3.17
x | Employees | 3 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 62.57% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -2.82% | ||
| 1 week | -3.64% | ||
| Current month | -5.49% | ||
| 1 month | -6.64% | ||
| 3 months | +14.83% | ||
| 6 months | -12.67% | ||
| Current year | -5.62% |
1 week
0.67
0.75
1 month
0.660.79
Current year
0.551.10
1 year
0.451.24
3 years
0.4514.44
5 years
0.4533.50
10 years
0.4533.50
| Managers | Title | Age | Since |
|---|---|---|---|
Petter Lindqvist
CEO | Chief Executive Officer | 72 | Jan. 08 |
Magnus Hurst
DFI | Director of Finance/CFO | 68 | Jan. 09 |
Roger Tell
CTO | Chief Tech/Sci/R&D Officer | 59 | 19-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Lars Erik Lind
CHM | Chairman | 83 | - |
Sten Nilsson
BRD | Director/Board Member | 76 | Jan. 03 |
Alain Herrera
BRD | Director/Board Member | 74 | 17-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-27 | 0.688 | -2.96% | 89 595 |
| 24-05-24 | 0.709 | -0.14% | 964,490 |
| 24-05-23 | 0.71 | -2.07% | 57,558 |
| 24-05-22 | 0.725 | -0.68% | 71,391 |
| 24-05-21 | 0.73 | +2.10% | 101,715 |
Delayed Quote Nasdaq Stockholm, May 27, 2024 at 04:43 am EDT
More quotes
Isofol Medical AB (publ) is a Sweden-based clinical stage pharmaceutical company. Its primary product is Modufolin, the active metabolite. Modufolin is a folate-based compound, which increases the efficiency and reduces the side effects of chemotherapy. Modufolin contains the key active substance methylenetetrahydrofolate (MTHF), which is the active metabolite in all folate-based medicines and therefore does not require metabolic activation to exert its action. The Company cooperates with pharmaceutical manufacturer Merck & Co Inc, as well as the Company has a worldwide supply and licence agreement for the use of Modufolin in cancer treatment. The Companyâs main shareholders are Biofol AB and Yield Life Science AB.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -5.62% | 10.76M | |
| +16.38% | 79.16B | |
| +8.99% | 8.72B | |
| -16.83% | 4.79B | |
| +47.36% | 4.62B | |
| +1.74% | 3.82B | |
| +14.51% | 2.33B | |
| -26.23% | 2.2B | |
| +15.63% | 2.1B | |
| -34.87% | 2.04B |
- Stock Market
- Equities
- ISOFOL Stock
